{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:46:04Z","timestamp":1761561964929},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T00:00:00Z","timestamp":1426809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s12072-015-9624-2","type":"journal-article","created":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T02:39:16Z","timestamp":1426732756000},"page":"424-430","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b"],"prefix":"10.1007","volume":"9","author":[{"given":"Yosuke","family":"Hirotsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiko","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yokosuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,20]]},"reference":[{"issue":"3 Suppl 1","key":"9624_CR1","doi-asserted-by":"crossref","first-page":"34S","DOI":"10.1002\/hep.510260706","volume":"26","author":"AM Bisceglie Di","year":"1997","unstructured":"Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26(3 Suppl 1):34S\u201338S","journal-title":"Hepatology"},{"key":"9624_CR2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","volume":"10","author":"B Hajarizadeh","year":"2013","unstructured":"Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553\u2013562","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"9624_CR3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-142-2-200501180-00009","volume":"142","author":"Y Shiratori","year":"2005","unstructured":"Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105\u2013114","journal-title":"Ann Intern Med"},{"key":"9624_CR4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jhep.2008.04.012","volume":"49","author":"S Deuffic-Burban","year":"2008","unstructured":"Deuffic-Burban S, Deltenre P, Louvet A, Canva V, Dharancy S, Hollebecque A, et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol. 2008;49:175\u2013183","journal-title":"J Hepatol"},{"key":"9624_CR5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12072-010-9193-3","volume":"4","author":"T Kanda","year":"2010","unstructured":"Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010;4:548\u2013561","journal-title":"Hepatol Int"},{"key":"9624_CR6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/rmv.534","volume":"17","author":"K Watashi","year":"2007","unstructured":"Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev Med Virol. 2007;17:245\u2013252","journal-title":"Rev Med Virol"},{"key":"9624_CR7","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1073\/pnas.0810950106","volume":"106","author":"V Schregel","year":"2009","unstructured":"Schregel V, Jacobi S, Penin F, Tautz N. Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3. Proc Natl Acad Sci USA. 2009;106:5342\u20135347","journal-title":"Proc Natl Acad Sci USA"},{"key":"9624_CR8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","volume":"376","author":"EJ Gane","year":"2010","unstructured":"Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467\u20131475","journal-title":"Lancet"},{"key":"9624_CR9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211\u2013221","journal-title":"N Engl J Med"},{"key":"9624_CR10","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604\u20131614","journal-title":"N Engl J Med"},{"key":"9624_CR11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594\u20131603","journal-title":"N Engl J Med"},{"key":"9624_CR12","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973\u20131982","journal-title":"N Engl J Med"},{"key":"9624_CR13","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","volume":"370","author":"P Ferenci","year":"2014","unstructured":"Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983\u20131992","journal-title":"N Engl J Med"},{"key":"9624_CR14","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12\u00a0weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879\u20131888","journal-title":"N Engl J Med"},{"key":"9624_CR15","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483\u20131493","journal-title":"N Engl J Med"},{"key":"9624_CR16","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u20131898","journal-title":"N Engl J Med"},{"key":"9624_CR17","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993\u20132001","journal-title":"N Engl J Med"},{"key":"9624_CR18","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083\u20132091","journal-title":"Hepatology"},{"key":"9624_CR19","doi-asserted-by":"crossref","first-page":"e73615","DOI":"10.1371\/journal.pone.0073615","volume":"8","author":"S Wu","year":"2013","unstructured":"Wu S, Kanda T, Nakamoto S, Jiang X, Miyamura T, Nakatani SM, et al. Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One. 2013;8:e73615","journal-title":"PLoS One"},{"key":"9624_CR20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","volume":"54","author":"F Suzuki","year":"2012","unstructured":"Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54:352\u2013354","journal-title":"J Clin Virol"},{"key":"9624_CR21","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3748\/wjg.v20.i11.2902","volume":"20","author":"S Nakamoto","year":"2014","unstructured":"Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014;20:2902\u20132912","journal-title":"World J Gastroenterol"},{"key":"9624_CR22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","volume":"58","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655\u2013662","journal-title":"J Hepatol"},{"key":"9624_CR23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/1471-2164-13-341","volume":"13","author":"MA Quail","year":"2012","unstructured":"Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genom. 2012;13:341","journal-title":"BMC Genom"},{"key":"9624_CR24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nbt.2522","volume":"31","author":"S J\u00fcnemann","year":"2013","unstructured":"J\u00fcnemann S, Sedlazeck FJ, Prior K, Albersmeier A, John U, Kalinowski J, et al. Updating benchtop sequencing performance comparison. Nat Biotechnol. 2013;31:294\u2013296","journal-title":"Nat Biotechnol"},{"key":"9624_CR25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","volume":"366","author":"AS Lok","year":"2012","unstructured":"Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216\u2013224","journal-title":"N Engl J Med"},{"key":"9624_CR26","doi-asserted-by":"crossref","unstructured":"Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014;384:1597\u20131605","DOI":"10.1016\/S0140-6736(14)61059-X"},{"key":"9624_CR27","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641\u20133650","journal-title":"Antimicrob Agents Chemother"},{"key":"9624_CR28","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","volume":"87","author":"DJ Bartels","year":"2013","unstructured":"Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87:1544\u20131553","journal-title":"J Virol"},{"key":"9624_CR29","doi-asserted-by":"crossref","first-page":"E360","DOI":"10.1111\/hepr.12316","volume":"44","author":"M Miura","year":"2014","unstructured":"Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360\u2013E367","journal-title":"Hepatol Res"},{"key":"9624_CR30","doi-asserted-by":"crossref","unstructured":"Applegate TL, Gaudieri S, Plauzolles A, Chopra A, Grebely J, Lucas M, et al. Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C. Antivir Ther 2014. doi: 10.3851\/IMP2821 . [Epub ahead of print]","DOI":"10.3851\/IMP2821"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9624-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-015-9624-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9624-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:37:19Z","timestamp":1559432239000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-015-9624-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,20]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["9624"],"URL":"https:\/\/doi.org\/10.1007\/s12072-015-9624-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,20]]}}}